Top Stories
Latest Coverage
Nature Breakthrough Study: The Technology Behind 83% Tumor Elimination — TGX-007 Synthetic Super Enhancer Therapy
As cancer treatment continues to evolve toward greater precision and system-level approaches, a cutting-edge study pu...
As cancer treatment continues to evolve toward greater precision and system-level approaches, a cutting-edge study pu...
Peptide-Drug Conjugates (PDC): The Next Frontier After ADC in Precision Oncology
Peptide-Drug Conjugates (PDC): The Next Frontier After ADC in Precision Oncology
Peptide-Drug Conjugates (PDC): The Next Frontier After ADC in Precision Oncology
Bispecific Antibodies Surge in 2026: From Hematologic Malignancies to Solid Tumors — New Data on T-Cell Engagers and Multispecific Antibodies
As we enter 2026, bispecific antibodies (BsAbs) are rapidly transitioning from an innovation-driven modality to a mai...
As we enter 2026, bispecific antibodies (BsAbs) are rapidly transitioning from an innovation-driven modality to a mai...
Latest Clinical Trial Update and Real-World Cases: Which CAR-T, Bispecific Antibody, and Gene Therapies Are Accessible to Patients?
Latest Clinical Trial Update and Real-World Cases: Which CAR-T, Bispecific Antibody, and Gene Therapies Are Accessibl...
Latest Clinical Trial Update and Real-World Cases: Which CAR-T, Bispecific Antibody, and Gene Therapies Are Accessibl...
Breakthrough with CAR-NK Plus PD-1: Survival in Advanced Colorectal Cancer Exceeds 700 Days
Breakthrough with CAR-NK Plus PD-1: Survival in Advanced Colorectal Cancer Exceeds 700 Days
Breakthrough with CAR-NK Plus PD-1: Survival in Advanced Colorectal Cancer Exceeds 700 Days
China’s First Original Radiopharmaceutical Approved: 99mTc-Pexidartide (Giluntai) Enables Precision Lung Cancer Diagnosis
China’s First Original Radiopharmaceutical Approved: 99mTc-Pexidartide (Giluntai)
China’s First Original Radiopharmaceutical Approved: 99mTc-Pexidartide (Giluntai)
